Loading cancer entity…
Loading cancer entity…
Clinical trials
91 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (9)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04858334 | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | recruiting | Phase 2 | 152 | National Cancer Institute (NCI)NIH | 3 | Sep 25, 2026 | clinicaltrials |
| NCT00977574 | Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer | active not recruiting | Phase 2 | 349 | National Cancer Institute (NCI) |
| 1 |
| Sep 9, 2026 |
| clinicaltrials |
| NCT02257528 | Nivolumab in Treating Patients With Persistent, Recurrent, or Metastatic Cervical Cancer | active not recruiting | Phase 2 | 26 | National Cancer Institute (NCI)NIH | 1 | Sep 8, 2026 | clinicaltrials |
| NCT02133196 | T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer | recruiting | Phase 2 | 85 | National Cancer Institute (NCI)NIH | 1 | Aug 31, 2026 | clinicaltrials |
| NCT00334815 | Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | active not recruiting | Phase 2 | 29 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04929041 | Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative | active not recruiting | Phase 2 / Phase 3 | 427 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04896073 | Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP) | completed | Phase 2 | 16 | National Cancer Institute (NCI)NIH | 1 | Aug 14, 2026 | clinicaltrials |
| NCT06543576 | External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer | recruiting | Phase 1 / Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT02186847 | Chemotherapy and Radiation Therapy With or Without Metformin Hydrochloride in Treating Patients With Stage III Non-small Cell Lung Cancer | completed | Phase 2 | 170 | NRG OncologyOTHER | 3 | Jul 13, 2026 | clinicaltrials |
| NCT07665684 | Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer(SONIC) | not yet recruiting | Phase 1 / Phase 2 | 67 | University Health Network, TorontoOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT05639972 | E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers | recruiting | Phase 1 / Phase 2 | 15 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05686226 | E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers | recruiting | Phase 2 | 20 | Christian HinrichsOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT05419479 | Switch Maintenance in Pancreatic | suspended | Phase 1 / Phase 2 | 46 | James Cleary, MD, PhDOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT05988918 | Multicenter Trial of ESK981 in Patients With Select Solid Tumors | active not recruiting | Phase 2 | 17 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 14, 2026 | clinicaltrials |
| NCT07276360 | Hypofractionated Radiotherapy for the Treatment of Locally Advanced Cervical Cancer in Uganda(HypoRTCx-UG) | recruiting | Phase 2 | 278 | Uganda Cancer InstituteOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06115499 | The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer | active not recruiting | Phase 2 / Phase 3 | 10 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 7, 2026 | clinicaltrials |
| NCT01935934 | Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer | completed | Phase 2 | 102 | National Cancer Institute (NCI)NIH | 2 | Oct 1, 2025 | clinicaltrials |
| NCT07153952 | RT for Adenocarcinoma/Adenosquamous Carcinoma | active not recruiting | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT06805864 | Pembrolizumab Concurrent With and Following Carbon-ion Radiotherapy for Locally Advanced Cervical Adenocarcinoma(BROTHER) | not yet recruiting | Phase 2 | 45 | Gunma UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02921269 | Atezolizumab and Bevacizumab in Treating Patients With Recurrent, Persistent, or Metastatic Cervical Cancer | completed | Phase 2 | 11 | National Cancer Institute (NCI)NIH | 1 | Feb 21, 2023 | clinicaltrials |
| NCT03834571 | Testing the Addition of Paclitaxel and Carboplatin Given After Standard Chemotherapy and Radiation for Cervical Cancer in HIV-positive Women | withdrawn | Phase 2 | 0 | AIDS Malignancy ConsortiumNETWORK | 2 | Jun 21, 2022 | clinicaltrials |
| NCT01307631 | Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer | completed | Phase 2 | 37 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2022 | clinicaltrials |
| NCT02394652 | The Potential for Metformin to Improve Tumor Oxygenation in Locally Advanced Cervix Cancer: A Phase II Randomized Trial | completed | Phase 2 | 16 | University Health Network, TorontoOTHER | 1 | Apr 21, 2021 | clinicaltrials |
| NCT01266460 | Vaccine Therapy in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 54 | Gynecologic Oncology GroupNETWORK | 1 | Sep 11, 2020 | clinicaltrials |
| NCT00924066 | Ixabepilone to Treat Cervical Cancer | terminated | Phase 2 | 41 | National Cancer Institute (NCI)NIH | 1 | Nov 21, 2019 | clinicaltrials |
| NCT01132820 | Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT01266447 | Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2019 | clinicaltrials |
| NCT00126581 | Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer | completed | Phase 2 | 188 | National Cancer Institute (NCI)NIH | 1 | Aug 7, 2019 | clinicaltrials |
| NCT00416455 | Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer | completed | Phase 1 / Phase 2 | 384 | National Cancer Institute (NCI)NIH | 4 | Jul 23, 2019 | clinicaltrials |
| NCT01011933 | Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 54 | National Cancer Institute (NCI)NIH | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01267253 | Brivanib Alaninate in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 31 | Gynecologic Oncology GroupNETWORK | 1 | Mar 20, 2019 | clinicaltrials |
| NCT00309959 | ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 37 | Gynecologic Oncology GroupNETWORK | 1 | Jan 8, 2019 | clinicaltrials |
| NCT02868892 | A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas | terminated | Phase 2 | 6 | Western Regional Medical CenterOTHER | 1 | Nov 2, 2018 | clinicaltrials |
| NCT03469531 | Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer | unknown | Phase 2 | 100 | Zhujiang HospitalOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00369122 | Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer | completed | Phase 2 | 60 | National Cancer Institute (NCI)NIH | 2 | Mar 20, 2018 | clinicaltrials |
| NCT01005329 | Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer | completed | Phase 2 | 34 | National Cancer Institute (NCI)NIH | 3 | Mar 15, 2018 | clinicaltrials |
| NCT01210222 | Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer | completed | Phase 2 | 35 | Gynecologic Oncology GroupNETWORK | 1 | Feb 23, 2018 | clinicaltrials |
| NCT00820898 | Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer | completed | Phase 2 | 24 | Gynecologic Oncology GroupNETWORK | 1 | Dec 29, 2017 | clinicaltrials |
| NCT00570674 | Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck | terminated | Phase 1 / Phase 2 | 29 | Dana-Farber Cancer InstituteOTHER | 0 | Nov 13, 2017 | clinicaltrials |
| NCT00039442 | Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer | completed | Phase 2 | 21 | Gynecologic Oncology GroupNETWORK | 1 | Aug 24, 2017 | clinicaltrials |
| NCT01294306 | MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy | completed | Phase 2 | 80 | National Cancer Institute (NCI)NIH | 1 | Nov 29, 2016 | clinicaltrials |
| NCT00064025 | Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus | completed | Phase 2 | 75 | Gynecologic Oncology GroupNETWORK | 1 | Apr 11, 2016 | clinicaltrials |
| NCT00057863 | Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Nov 17, 2015 | clinicaltrials |
| NCT01026792 | Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery | completed | Phase 2 | 38 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2015 | clinicaltrials |
| NCT01093222 | Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jun 30, 2015 | clinicaltrials |
| NCT00217633 | Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer | completed | Phase 2 | 38 | Gynecologic Oncology GroupNETWORK | 2 | May 29, 2015 | clinicaltrials |
| NCT00389974 | Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Feb 16, 2015 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials